<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">16038370</PMID>
      <DateCompleted>
        <Year>2005</Year>
        <Month>08</Month>
        <Day>18</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>01</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Print">1726-4901</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>68</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2005</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the Chinese Medical Association : JCMA</Title>
          <ISOAbbreviation>J Chin Med Assoc</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan.</ArticleTitle>
        <Pagination>
          <StartPage>307</StartPage>
          <EndPage>314</EndPage>
          <MedlinePgn>307-14</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The purpose of this study was to evaluate the efficacy and safety of nafarelin, a gonadotropin-releasing hormone (GnRH) analogue, versus danazol in the treatment of women with endometriosis in Taiwan.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Fifty-nine women with laparoscopically and pathologically confirmed endometriosis were randomized to receive nafarelin or danazol for 180 days. Efficacy was assessed from mean changes in laparoscopy score (LS) and total symptom severity score (TSSS). Adverse events (AEs) and laboratory parameters, including hematology, hepatic function, blood pressure, and lipid levels, were monitored for safety evaluations.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">All demographic and baseline factors, except body weight, were comparable between the 2 treatment groups. Both nafarelin and danazol satisfactorily resolved pelvic tenderness, induration, pelvic pain, dysmenorrhea and dyspareunia. No significant differences were noted in efficacy endpoints between nafarelin and danazol regarding LS and TSSS at 90 and 180 days of treatment. No significant difference was observed between the 2 groups regarding the overall incidence of AEs, except for laboratory-related AEs. However, nafarelin tended to have less impact than danazol on aspartate transaminase and alanine transaminase, and nafarelin was better tolerated than danazol regarding changes in lipid profiles. Both treatments had little or no effect on hematologic parameters.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Nafarelin and danazol demonstrated similar clinical efficacy, but nafarelin was associated with fewer laboratory changes and a stable lipid profile, relative to danazol. Moreover, intranasally administered nafarelin is noninvasive, and may be a more comfortable and safer alternative to slow-release injectable GnRH agonists. Based on this study, we suggest that nafarelin, like other GnRH analogues, may be a treatment of choice for Taiwanese women with endometriosis. However, direct comparative studies of nafarelin with slow-release injectable GnRH agonists are now required.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Ming-Huei</ForeName>
            <Initials>MH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Bill Ken-Jen</ForeName>
            <Initials>BK</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chang</LastName>
            <ForeName>Sheng-Ping</ForeName>
            <Initials>SP</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Peng-Hui</ForeName>
            <Initials>PH</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016430">Clinical Trial</PublicationType>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>J Chin Med Assoc</MedlineTA>
        <NlmUniqueID>101174817</NlmUniqueID>
        <ISSNLinking>1726-4901</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008076">Cholesterol, HDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>1X0094V6JV</RegistryNumber>
          <NameOfSubstance UI="D017274">Nafarelin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.6.1.1</RegistryNumber>
          <NameOfSubstance UI="D001219">Aspartate Aminotransferases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.6.1.2</RegistryNumber>
          <NameOfSubstance UI="D000410">Alanine Transaminase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>N29QWW3BUO</RegistryNumber>
          <NameOfSubstance UI="D003613">Danazol</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000410" MajorTopicYN="N">Alanine Transaminase</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001219" MajorTopicYN="N">Aspartate Aminotransferases</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008076" MajorTopicYN="N">Cholesterol, HDL</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008078" MajorTopicYN="N">Cholesterol, LDL</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003613" MajorTopicYN="N">Danazol</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004715" MajorTopicYN="N">Endometriosis</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="N">Liver</DescriptorName>
          <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017274" MajorTopicYN="N">Nafarelin</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2005</Year>
          <Month>7</Month>
          <Day>26</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2005</Year>
          <Month>8</Month>
          <Day>19</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2005</Year>
          <Month>7</Month>
          <Day>26</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">16038370</ArticleId>
        <ArticleId IdType="doi">10.1016/S1726-4901(09)70166-2</ArticleId>
        <ArticleId IdType="pii">S1726-4901(09)70166-2</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
